The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER(+) Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Oral selective estrogen receptor degraders (SERD) could become the backbone of endocrine therapy (ET) for estrogen receptor–positive (ER(+)) breast cancer, as they achieve greater inhibition of ER-driven cancers than current ETs and overcome key resistance mechanisms. In this study, we evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawson, Mandy, Cureton, Natalie, Ros, Susana, Cheraghchi-Bashi, Azadeh, Urosevic, Jelena, D'Arcy, Sophie, Delpuech, Oona, DuPont, Michelle, Fisher, David I., Gangl, Eric T., Lewis, Hilary, Trueman, Dawn, Wali, Neha, Williamson, Stuart C., Moss, Jennifer, Montaudon, Elodie, Derrien, Heloise, Marangoni, Elisabetta, Miragaia, Ricardo J., Gagrica, Sladjana, Morentin-Gutierrez, Pablo, Moss, Thomas A., Maglennon, Gareth, Sutton, Daniel, Polanski, Radoslaw, Rosen, Alan, Cairns, Jonathan, Zhang, Pei, Sánchez-Guixé, Mònica, Serra, Violeta, Critchlow, Susan E., Scott, James S., Lindemann, Justin P.O., Barry, Simon T., Klinowska, Teresa, Morrow, Christopher J., S Carnevalli, Larissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690091/
https://www.ncbi.nlm.nih.gov/pubmed/37725704
http://dx.doi.org/10.1158/0008-5472.CAN-23-0694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690091/
https://www.ncbi.nlm.nih.gov/pubmed/37725704
http://dx.doi.org/10.1158/0008-5472.CAN-23-0694

Ejemplares similares